Study author of SPOT-MAS clinical validation – a ctDNA-based assay for multi-cancer detection – to present at 2023 ASCO Breakthrough Official Press Program – Yokohama, Japan.
Thursday, August 3 at 12:00-13:00 JST
Location: Pacifico Yokohama.
The American Society of Clinical Oncology is a leading, global society of more than 45,000 oncology professionals in over 150 countries.
This year ASCO Breakthrough Meeting in Yokohama, Japan brings the world’s top oncology professionals to reveal how utting-edge advances in cancer care technology and innovations can help transform cancer care.
Out of 160 abstracts being presented in Yokohama, four abstracts were chosen for ASCO Official Press Program.
Besides 03 authors from Japan, China and Australia, Dr. Le Son Tran from the Medical Genetics Institute of Ho Chi Minh City, Vietnam will discuss an interim report of the clinical validation of SPOT-MAS, an ctDNA-based assay for multi-cancer detection.
Dr. Le Son Tran will share the latest updates from the research as well as highlighting key findings. The Abstract “Clinical validation of a ctDNA-based assay for multi-cancer detection: A Vietnamese longitudinal prospective cohort study of 2,795 participants” will also be presented at the Poster Session B, Aug 4.
Keep in touch with us to learn more about key findings and ASCO experts’ opinion after the session.
—
Dr. Le Son Tran – Senior Scientist at Medical Genetics Institute, Ho Chi Minh City is the leading researcher of the SPOT-MAS assay, a multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization.
The SPOT-MAS assay contributes 02 abstracts at this year ASCO Breakthrough, while another abstract of Minimal Residual Disease (MRD) “Personalized K-Track Assay to Detect Actionable Mutations and Minimal Residual Disease in Solid Tumors” from study author Dr. Lan Tu, Prinicipal Investigator (R&D) of Gene Solutions received an Abstract Award (Top 40 highest scoring abstracts submitted to the 2023 ASCO Breakthrough Meeting).
ASCO Breakthrough is endorsed by the Japan Ministry of Health, Labor, and Welfare.
Previously, another study from Dr. Le Son Tran was also highlighted at eLife Science press release after the Reviewed Preprint “Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization” published.
